Aspects concerning busulfan pharmacokinetics and bioavailability.

Aspects concerning busulfan pharmacokinetics and bioavailability.

Item
http://www.wikidata.org/entity/Q41178776
Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthaseNon-myeloablative stem cell transplants.Myelosuppressive conditioning using busulfan enables bone marrow cell accumulation in the spinal cord of a mouse model of amyotrophic lateral sclerosis.Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation.Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation.Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.Bone Marrow-Derived Cell Accumulation in the Spinal Cord Is Independent of Peripheral Mobilization in a Mouse Model of Amyotrophic Lateral Sclerosis.A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists.Complete Remission of a Refractory Acute Myeloid Leukemia with Myelodysplastic- and Monosomy 7-Related Changes after a Combined Conditioning Regimen of Plerixafor, Cytarabine and Melphalan in a 4-Year-Old Boy: A Case Report and Review of Literature
P2860

Aspects concerning busulfan pharmacokinetics and bioavailability.

Item
http://www.wikidata.org/entity/Q41178776
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Aspects concerning busulfan pharmacokinetics and bioavailability.
@en
type
label
Aspects concerning busulfan pharmacokinetics and bioavailability.
@en
prefLabel
Aspects concerning busulfan pharmacokinetics and bioavailability.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Aspects concerning busulfan pharmacokinetics and bioavailability.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698